| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_44c65dde39087f2b370566f5a8d46085 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-135
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5078
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-135
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61J3-06 |
| filingDate |
2011-02-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2017-01-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_981947fef169c019c8a1858193480a79
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_787b95a48ce96b18163b180121a5bec1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e95941d2ae31324ed0afc6b7bf27c20e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cddc1f95e408947a1ffd5559d7cb145d |
| publicationDate |
2017-01-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
RU-2607595-C2 |
| titleOfInvention |
Rasagiline compositions of prolonged release and use thereof |
| abstract |
FIELD: pharmaceutics. n SUBSTANCE: group of inventions refers to pharmaceutics. Oral pharmaceutical composition is described in form of prolonged release for treating neurodegenerative disease or damage of nervous system. Above composition contains R(+)-N-propargyl-1-aminoindan (rasagiline) as active substance. Composition contains pellets with prolonged release and pharmaceutically acceptable carrier. Said pellet includes: I) inert core of pellet; II) layer with active substance, polyvinyl pyrrolidone and talc; III) optionally insulating layer with polyvinyl pyrrolidone; IV) prolonged release coating layer with ethylcellulose and polyethylene glycol. Use of said composition and method of treating neurodegenerative disease or damage of nervous system are also described. n EFFECT: invention provides intensified effect on above diseases. n 16 cl, 9 dwg, 17 tbl, 11 ex |
| priorityDate |
2010-02-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |